RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
Polyneuropathy associated with anti-MAG monoclonal IgM gammopathy is responsive of mainly a
sensory deficit in predominantly males ,aged 40-70 years. Significantly high serum anti-MAG
antibodies are linked with demyelinating features of the peripheral nerves.Rituximab, an
anti-CD 20 monoclonal antibody is a new drug which reduces B-lymphocytes. This study will
test the safety and efficacy of rituximab in the treatment of patients with anti-MAG
polyneuropathy.
Phase:
Phase 3
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
Groupe Hospitalier Pitie-Salpetriere Henri Mondor University Hospital Hospices Civils de Lyon University Hospital, Basel, Switzerland University Hospital, Bordeaux University Hospital, Limoges University Hospital, Marseille